Brooks Laboratories (BOM:533543) Other Financing: ₹0.0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:533543 Brooks Laboratories Ltd BOM:533543
57 GF Score
Price ₹62.95
GF Value ₹118.29
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Brooks Laboratories Other Financing?

Brooks Laboratories BOM:533543 +3.20% 57 Other Financing is ₹0.0 Mil as of Mar. 2026. GuruFocus rates BOM:533543 with a GF Score™ of 57/100 and a GF Value™ of ₹118.29 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Brooks Laboratories's Other Financing for the three months ended in Mar. 2026 was ₹0.0 Mil.

Brooks Laboratories's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.0 Mil.

Brooks Laboratories Other Financing Historical Data

* Premium members only.

The historical data trend for Brooks Laboratories's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Brooks Laboratories Other Financing Chart

Brooks Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 713.22 154.46 -6.76 -8.33 -7.63

Brooks Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:533543
57GF Score
Brooks Laboratories Ltd BOM:533543
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Brooks Laboratories Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of ₹0.0 Mil mean?
Brooks Laboratories (BOM:533543) has a Other Financing of ₹0.0 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Brooks Laboratories and its competitors.
Is Brooks Laboratories' Other Financing too high?
Brooks Laboratories' current Other Financing is ₹0.0 Mil. Overall, Brooks Laboratories has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Brooks Laboratories' Other Financing compare to ZTS?
Brooks Laboratories' Other Financing of ₹0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Drug Manufacturers company?
A good Other Financing depends on the Drug Manufacturers industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Brooks Laboratories and its competitors. Brooks Laboratories's current Other Financing is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brooks Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Brooks Laboratories (BOM:533543) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹118.29, compared to a current price of ₹62.95 — trading 46.8% below its estimated fair value. The current Other Financing is ₹0.0 Mil. Brooks Laboratories' overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Brooks Laboratories (BOM:533543), the current Other Financing is ₹0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Brooks Laboratories (BOM:533543) Overvalued in 2026?

Based on GuruFocus' analysis, Brooks Laboratories stock appears to be undervalued. The current stock price of ₹62.95 is trading 46.8% below its estimated GF Value™ of ₹118.29. GuruFocus considers Brooks Laboratories to be Significantly Undervalued.

Key valuation signals for BOM:533543:

  • Other Financing: ₹0.0 Mil
  • GF Value™: ₹118.29 vs. price of ₹62.95 (46.8% below fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the BOM:533543 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Brooks Laboratories Business Description

Other Exchanges BROOKS:India
Address Near Andheri Kurla Road, 201, The Summit Business Park, Behind Guru Nanak Petrol Pump, Andheri (East), Mumbai, MH, IND, 400 093
Brooks Laboratories Ltd is a pharmaceutical manufacturer focused on developing and producing a broad range of generic medicines. Its key segments include injectables, tablets, and dry syrups, with product lines covering antibiotics such as beta-lactams and cephalosporins as well as general critical care injectables. The company operates manufacturing facilities compliant with international quality standards located in India, serving both domestic and international markets. Revenue is generated through contract manufacturing and sales of pharmaceutical formulations distributed broadly across regulated and semi-regulated international markets. The company has obtained regulatory certifications from multiple countries to comply with international standards for pharmaceutical manufacturing.
57GF Score

Get the complete analysis for BOM:533543

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹62.95
Price
₹118.29
GF Value